GlassScriptPhysician profile
Sara C Crystal
NPI 1992996110
$55,858.51
in general payments reported to CMS, 2019-2025
17 companies · $1,877 in 2025
The $1,877 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,922 · 2020: $16K · 2021: $19K · 2022: $9,758 · 2023: $5,584 · 2024: $1,674 · 2025: $1,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,690 · Consulting Fee: $1,525 · Food and Beverage: $920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,690.00 |
| Consulting Fee | $1,525.00 |
| Food and Beverage | $919.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22,916.19 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Allergan, INC. | $18,051.49 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $7,397.66 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $3,367.66 | 2022 | |
| Pfizer INC. | $1,725.90 | 2023-2025 | |
| Promius Pharma LLC | $1,058.71 | 2019 | |
| Sentynl Therapeutics, INC. | $517.00 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $232.20 | 2019-2023 | Austedo Xr |
| Novartis Pharmaceuticals Corporation | $159.55 | 2019-2021 | |
| Amgen INC. | $139.77 | 2020-2023 | Aimovig |
| Upsher-Smith Laboratories LLC | $101.45 | 2021 | |
| Supernus Pharmaceuticals, INC. | $76.90 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $33.14 | 2024-2025 | Onzetra Xsail |
| Amneal Pharmaceuticals LLC | $23.97 | 2025 | Brekiya |
| Vertical Pharmaceuticals, LLC | $22.98 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $18.80 | 2025 | |
| Lundbeck LLC | $15.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Crystal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.